Acutaas Chemicals Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹330Cr
- +59.4% YoY
- −23.8% QoQ
- Net profit
- ₹75Cr
- +70.5% YoY
- −44% QoQ
- Margin
- 34%
- +9 pp YoY
- −8 pp QoQ
Guidance rank: #17 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
The company targets a 25% revenue growth for the full financial year FY '27. Company targets a 25% revenue growth for FY '27, confident to maintain similar EBITDA margins as FY '26 despite higher revenue.
From Acutaas Chemicals Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- The company targets a 25% revenue growth for the full financial year FY '27.
- Battery chemicals business expected to ramp up to full capacity utilization (4,000 MT) by FY '29, indicating strong volume growth.
- Semiconductor business (Indichem plant) to start contributing revenues from FY '28 and expected to reach full capacity within 3-4 years.
- Pharma Intermediates, including CDMO business, expected to grow strongly, with CDMO revenue target of INR 1,000 crores and confident to exceed it.
- Spec Chem business revenue mix to grow due to battery chemicals and new higher-margin specialty chemicals despite phasing out commodity chemicals.
2 more points from Acutaas Chemicals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Acutaas Chemicals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY '27 capex estimated at around INR 90-95 crores, including:
- Spillover capex of electrolyte additives and pilot plant capex (~INR 50 crores)
- Maintenance capex of INR 40-45 crores
- Additional capex planned for a new R&D center and land acquisition for future capacity expansion; details to be announced when finalized.
- Land acquisition is intended to support capacity expansion for the Pharma Intermediate business as existing plants (Sachin and Ankleshwar) approach full utilization by FY '28.
- Indichem plant construction is ahead of schedule, with capex completion expected by end of Q1 FY '27; revenue anticipated from next financial year.
2 more points from Acutaas Chemicals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Acutaas Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Acutaas Chemicals Ltd's call on order book
Create a free account to keep reading this call
Acutaas Chemicals Ltd — Quarterly revenue & net profit
Acutaas Chemicals Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 330 | 207 | +59.4% | 433 | -23.8% |
| Operating profit (EBITDA) | 113 | 51 | +121.6% | 184 | -38.6% |
| Operating margin | 34% | 25% | +9 pp | 42% | -8 pp |
| Profit before tax | 104 | 58 | +79.3% | 184 | -43.5% |
| Net profit (PAT) | 75 | 44 | +70.5% | 134 | -44% |
| EPS (₹) | 9.07 | 5.41 | +67.7% | 16.09 | -43.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹437 Cr, net profit ₹123 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Acutaas Chemical's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Acutaas Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Acutaas Chemicals Ltd Q1 FY27 results?
The company targets a 25% revenue growth for the full financial year FY '27. Company targets a 25% revenue growth for FY '27, confident to maintain similar EBITDA margins as FY '26 despite higher revenue.
What is Acutaas Chemicals Ltd share price analysis?
Acutaas Chemicals Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 72.9 with a market cap of ₹28,166 Cr. Investors should review the full earnings analysis for detailed insights.
Is Acutaas Chemicals Ltd planning capital expenditure?
FY '27 capex estimated at around INR 90-95 crores, including: - Spillover capex of electrolyte additives and pilot plant capex (~INR 50 crores) - Maintenance capex of INR 40-45 crores - Additional capex planned for a new R&D center and land acquisition for future capacity expansion; details to be announced when finalized.
Keep Acutaas Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
